Quantum Biopharma (TSE:QNTM) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Quantum BioPharma’s safety review committee has recommended moving forward with dosing the second cohort in its Phase 1 clinical trial for Lucid-21-302, targeting multiple sclerosis. This decision comes after positive safety evaluations from the first cohort, marking a significant step in the company’s innovative drug development efforts.
For further insights into TSE:QNTM stock, check out TipRanks’ Stock Analysis page.
